Prior strategies to mitigate hepatic dysfunction have focused on adjusting dosimetric parameters and exclusion of patients with advanced cirrhosis.2,5 Other approaches have used imaging biomarkers6 and early changes in circulating serum hepatocyte growth factor (HGF)7. The gene discussed is HGF; the disease is Cirrhosis.